Bioextrax AB (publ)
Stockholm Stock ExchangeTotal Valuation
Bioextrax AB (publ) carries a market capitalization of 112.72M, placing it among publicly traded companies globally.
| Market Cap | 112.72M |
| Enterprise Value | N/A |
Share Statistics
Bioextrax AB (publ) currently has 47.60M shares outstanding.
| Shares Outstanding | 47.60M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 134.29, and the price-to-book ratio stands at 6.86.
| PE Ratio | N/A |
| PS Ratio | 134.29 |
| PB Ratio | 6.86 |
| P/TBV Ratio | 6.86 |
| P/FCF Ratio | -8.89 |
| P/OCF Ratio | -8.75 |
Financial Position
Bioextrax AB (publ) maintains a current ratio of 6.32, meaning it holds 6.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.32 |
| Quick Ratio | 5.47 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -18,178.00 |
Financial Efficiency
| Return on Equity (ROE) | -92.65 |
| Return on Assets (ROA) | -84.31 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Bioextrax AB (publ)'s stock has declined approximately -3.10345% over the past 52 weeks. The 50-day moving average sits at 2.56, while the 200-day moving average is 2.53.
| Beta (5Y) | N/A |
| 52-Week Price Change | -3.10345% |
| 50-Day Moving Average | 2.56 |
| 200-Day Moving Average | 2.53 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Bioextrax AB (publ) generated 863,000.00 in revenue and converted that into -18.05M in net income, yielding earnings per share of -0.43. EBITDA reached -18.18M, while operating income came in at -18.18M.
| Revenue | 863,000.00 |
| Gross Profit | -294,000.00 |
| Operating Income | -18.18M |
| Pretax Income | -18.05M |
| Net Income | -18.05M |
| EBITDA | -18.18M |
| EBIT | -18.18M |
| Earnings Per Share (EPS) | -0.43 |
Balance Sheet
Total book value stands at 16.89M, with working capital of 11.25M providing operational flexibility.
| Cash & Cash Equivalents | 11.56M |
| Total Debt | N/A |
| Net Debt | -11.56M |
| Equity (Book Value) | 16.89M |
| Book Value Per Share | 0.41 |
| Working Capital | 11.25M |
Cash Flow
Bioextrax AB (publ) produced -13.24M in operating cash flow over the past twelve months. After subtracting -46,000.00 in capital expenditures, free cash flow totaled -13.28M - equivalent to -0.32 per share.
| Operating Cash Flow | -13.24M |
| Capital Expenditures | -46,000.00 |
| Free Cash Flow | -13.28M |
| FCF Per Share | -0.32 |
Margins
Bioextrax AB (publ) operates with a gross margin of -34.07, reflecting its pricing power and cost economics. The operating margin of -2,106.37 and net profit margin of -2,091.19 provide insight into operational efficiency.
| Gross Margin | -34.07 |
| Operating Margin | -2,106.37 |
| Pretax Margin | -2,091.19 |
| Profit Margin | -2,091.19 |
| EBITDA Margin | -2,106.37 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -11.10 |
| FCF Yield | -11.24 |
Scores
Bioextrax AB (publ) posts an Altman Z-Score of 31.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 31.56 |